 On Thursday, shares of ChemoCentryx Inc. CCXI , Financial shot up more than 110 before closing the day at 50.43 on the news that the small-cap biotech company has entered into an agreement to be acquired by major drugmaker Amgen Inc. AMGN , Financial in an all-cash deal worth 3.7 billion, or 52 per share. 